Polydopamine-Reinforced Hemicellulose-Based Multifunctional Flexible Hydrogels for Human Movement Sensing and Self-Powered Transdermal Drug Delivery.

The preparation of bio-based hydrogels with excellent mechanical properties, stable electrochemical properties, and self-adhesive properties remains a challenge. In this study, nano-polydopamine-reinforced hemicellulose-based hydrogels with typical multistage pore structures were prepared. The nanocomposite hydrogels exhibit stable mechanical properties and show no significant crushing phenomenon after 1000 cycles of cyclic compression. Its ultimate tensile strain was 101%, which is significantly higher than that of native skin. The shear adhesion strength of the hydrogel to skin tissue reaches 7.52 kPa, which is better than fibrin glue (Greenplast) (5 kPa), and the excellent adhesion property prolongs the service time of the hydrogel in biomedicine applications. The impedance of the hydrogel was reduced and the electrical conductivity was increased with the addition of nano-polydopamine. The prepared nanocomposite hydrogel can detect various body movements (even throat vibrations) in real time as a motion sensor while being able to rapidly load cationic drugs and facilitate transdermal introduction of electrically stimulated drug ions as a drug patch. It provides theoretical support for the fabrication of hemicellulose-based hydrogels with excellent properties through molecular design and nanoparticle reinforcement. This has important implications for the development of next-generation flexible materials suitable for health monitoring and self-administration.

Significance of serum peptidylarginine deiminase type 4 in ANCA-associated vasculitis.

OBJECTIVE: To investigate the clinical significance of peptidylarginine deiminase type 4 (PAD4) in the pathogenesis of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). To make a primary observation on the relationship of chronic bronchitis and bronchiectasis (CB) with the pathogenesis of AAV by PAD4. METHODS: The sera from 13 patients with AAV, 13 patients with CB, 11 patients with rheumatoid arthritis (RA), 11 patients with primary chronic kidney disease (CKD) and 12 normal controls were collected. Serum PAD4 was detected using commercial ELISA kits. The serum levels of PAD4 were compared not only among the different groups but also between the activity and remission stage of the same disease. The associations between serum PAD4 and the Birmingham Vasculitis Activity Score (BVAS) of AAV were further investigated. RESULTS: (1) The serum levels of PAD4 in patients with AAV, RA and CB at activity stage were all higher than that in the normal controls (P<0.001, respectively, α'=0.007). The serum level of PAD4 in patients with CB at remission stage and that in CKD group were not found elevated compared with the normal controls (P=0.02, P=0.085, respectively, α'=0.007). (2) At activity stage, among the groups of simple AAV, AAV with a long history of CB and CB without AAV, no significant difference was detected. While at remission stage among the 3 groups, the serum level of PAD4 was at the lowest level in CB group without AAV. (3) The serum level of PAD4 in some patients with CB without AAV were found still higher at remission stage. (4) The serum level of PAD4 in AAV with renal damage at activity stage was positively correlated with BVAS (the activity score of AAV, r=0.71, P=0.02). CONCLUSION: PAD4 is involved in the pathogenesis of AAV. Whether some patients with CB might progress to AAV by the link with PAD4 still need further investigation.